Shares of Chinese high-tech biological enterprise Chongqing Zhifei Biological Products (SHE: 3001220) leapt 20% to 58.40 renminbi, on the news that it will to co-promote UK pharma major GSK's (LSE: GSK) shingles vaccine, Shingrix in China for an initial three-year period, with the potential to extend the partnership should all parties agree.
Set to start January 1, 2024, Zhifei will have exclusive rights to import and distribute Shingrix in China, focusing on promoting the vaccine through its extensive service network, which covers more than 30,000 vaccination points across the country. In partnership, GSK - as the license holder for the product - will co-promote Shingrix by raising awareness of the importance of shingles vaccination amongst healthcare professionals within community health centres and hospital settings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze